Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Teva Pharmaceutical Industries Limited
< Previous
1
2
3
4
5
Next >
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
December 14, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
December 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
November 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
SNY
TEVA
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
November 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
RPRX
TEVA
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
November 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
November 07, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
November 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
November 01, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
October 25, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
October 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
October 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
October 04, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
SNY
TEVA
Teva Announces Changes to Executive Management Team
September 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Settles Price Fixing Charges With U.S. DOJ
August 21, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
July 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
July 05, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
June 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
June 15, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
ALVO
TEVA
Teva Concludes Nationwide Opioids Settlement Agreement
June 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
June 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
May 20, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.